VIRIDIAN THERAPEUTICS INC
NASDAQ: VRDN (Viridian Therapeutics, Inc.)
Kemas kini terakhir: 7 jam lalu18.92
-0.98 (-4.92%)
| Penutupan Terdahulu | 19.90 |
| Buka | 19.66 |
| Jumlah Dagangan | 1,064,900 |
| Purata Dagangan (3B) | 2,539,645 |
| Modal Pasaran | 2,089,291,776 |
| Harga / Jualan (P/S) | 24.46 |
| Harga / Buku (P/B) | 4.22 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| Margin Operasi (TTM) | -130,369.45% |
| EPS Cair (TTM) | -3.35 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.82% |
| Nisbah Semasa (MRQ) | 19.49 |
| Aliran Tunai Operasi (OCF TTM) | -279.75 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -171.41 M |
| Pulangan Atas Aset (ROA TTM) | -32.62% |
| Pulangan Atas Ekuiti (ROE TTM) | -51.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Viridian Therapeutics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.17 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.16% |
| % Dimiliki oleh Institusi | 114.61% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |